Jane Street
ALLO icon

Jane Street’s Allogene Therapeutics ALLO Stock Holding History

Jane Street’s Portfolio ALLO Stock Details ALLO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$40.1K Buy
+19,300
New +$42.4K ﹤0.01% 11015
2023
Q4 		– Sell
-16,700
Closed -$52.9K – 9131
2023
Q3 		$52.9K Buy
+16,700
New +$73.2K ﹤0.01% 8137
2023
Q2 		– Sell
-16,700
Closed -$82.5K – 8606
2023
Q1 		$82.5K Buy
+16,700
New +$107K ﹤0.01% 8306
2022
Q4 		– Sell
-67,700
Closed -$731K – 9058
2022
Q3 		$731K Buy
67,700
+54,600
+417% +$742K ﹤0.01% 5980
2022
Q2 		$149K Buy
13,100
+1,100
+9% +$9.76K ﹤0.01% 8414
2022
Q1 		$109K Sell
12,000
-1,800
-13% -$18.7K ﹤0.01% 9413
2021
Q4 		$206K Buy
+13,800
New +$243K ﹤0.01% 8775
2021
Q3 		– Sell
-9,600
Closed -$250K – 9856
2021
Q2 		$250K Buy
+9,600
New +$274K ﹤0.01% 8459
2020
Q3 		– Sell
-5,600
Closed -$240K – 7093
2020
Q2 		$240K Buy
+5,600
New +$203K ﹤0.01% 6147

Other funds holding ALLO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Jane Street's ALLO Position: Q2 2026 in Review

Jane Street sold out of Allogene Therapeutics (ALLO) in Q2 2026, closing a stake of 505,273 shares — an estimated $1.11M sold.

Jane Street first reported a position in ALLO in Q3 2019 and held it in 24 quarters. The position peaked at $2.96M in Q4 2025. 209 funds tracked by Wall St. Rank hold ALLO as of Q2 2026.

  • Jane Street reported no remaining Allogene Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Jane Street sold 505,273 Allogene Therapeutics shares in Q2 2026, an estimated $1.11M.
  • Jane Street first reported a position in Allogene Therapeutics in Q3 2019 and held it in 24 quarters.
  • Jane Street's Allogene Therapeutics position peaked at $2.96M in Q4 2025.
  • 209 funds tracked by Wall St. Rank held Allogene Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.